Clinical Trial

Investigating a Tailored Diuretic Algorithm in Acute Heart Failure Patients

Study acronym: TAILOR-AHF
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 13, 2026 (before its estimated June 27, 2026 completion). Its status may not reflect the trial's current state.
Summary
Acutely decompensated heart failure (ADHF) is highly prevalent and has a high (financial) burden on the health care system. Treatment often consists of the administration of IV decongestive agents. Adequate dosing is difficult due to varying diuretic resistance and inadequate parameters to evaluate the response. Urine sodium is a promising biomarker to evaluate the diuretic response. It is hypothesized that a tailored, urine sodium guided diuretic algorithm will result in faster and more complete decongestion and therefore lead to better survival (in terms of mortality and heart failure events) while being non-inferior in terms of safety (mainly regression of kidney function).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-10-17; most recent amendment 2026-04-07.
Trial Details
NCT Number NCT06092437
Lead Sponsor Zuyderland Medisch Centrum
Conditions Heart Failure Acute
Enrollment 556 participants
Start Date 2023-02-27
Primary Completion 2026-06-27 (estimated)
Study Completion 2026-08-27 (estimated)
Updated on ClinicalTrials.gov 2026-04-13